




UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/509,249	09/28/2004	Shunichi Kuroda	12480-000067/US	4499
30593 7590 12/29/2009 HARNESS, DICKEY & PIERCE, P.L.C. P.O. BOX 8910 RESTON, VA 20195			EXAMINER PENG, BO	
			ART UNIT 1648	PAPER NUMBER
			MAIL DATE 12/29/2009	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

HDP DC 30/12/09 11:13

Matter no.	12480-000067/US		
Action Due Date	1/29/10	Final Date	6/29/10
Action	Resp. to Not. to comply Due NEP		
Atty	DJD/Eltt	DKT/Verify	K6/ent



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO. /CONTROL NO. 10509249	FILING DATE 9/28/2004	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION KURODA ET AL.	ATTORNEY DOCKET NO. 12480-000067/US
--	--------------------------	---	--

EXAMINER
BO PENG

ART UNIT 1648	PAPER 20091222
------------------	-------------------

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Web (<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>>, EFS Submission User Manual - ePAVE)
2. Mailed to:
Mail Stop Sequence
Commissioner for Patents
P.O. Box 22313 1450
Alexandria, VA 22313 1450
3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:
U.S. Patent and Trademark Office
Mail Stop Sequence
Customer Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Any inquiry concerning this communication should be directed to at telephone number (571)272-5542. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms, can be reached on

/BO PENG/
Primary Examiner, Art Unit 1648



=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2009; month=9; day=21; hr=11; min=11; sec=59; ms=20;]

=====

Reviewer Comments:

<150> 10/509,249

<151> 2004-09-28

Please remove these lines, since they are not prior application data.

<210> 30

<211> 39

<212> DNA

<213> artificial synthesized peptide sequence

<220>

<223> test fused

<400> 30

The above <213> response is invalid, per 1.823 of the Sequence Rules. The only valid responses are: the Genus species of the organism, "Artificial Sequence", or "Unknown". "Artificial Sequence" and "Unknown" require explanation in the <220>-<223> section; please clearly give the source of the genetic material. FYI: this is not a peptide sequence. Same error in Sequence 31.

Please ensure that all explanations of "Artificial Sequence" give the source of the genetic material.

Application No: 10509249

Version No: 6.0

Input Set:

Output Set:

Started: 2009-09-03 15:42:15.339

Finished: 2009-09-03 15:42:22.674

Elapsed: 0 hr(s) 0 min(s) 7 sec(s) 335 ms

Total Warnings: 245

Total Errors: 0

No. of SeqIDs Defined: 245

Actual SeqID Count: 245

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2009-09-03 15:42:15.339
Finished: 2009-09-03 15:42:22.674
Elapsed: 0 hr(s) 0 min(s) 7 sec(s) 335 ms.
Total Warnings: 245
Total Errors: 0
No. of SeqIDs Defined: 245
Actual SeqID Count: 245

Error code	Error Description
	This error has occurred more than 20 times, will not be displayed
W 402	Undefined organism found in <213> in SEQ ID (30)
W 402	Undefined organism found in <213> in SEQ ID (31)

SEQUENCE LISTING

<110> Japan Science and Technology Agency
Kuroda, Shunichi
Tanizawa, Katsuyuki
Okajima, Toshihide
Kondo, Akihiko
Ueda, Nasakazu
Seno, Masahura

<120> THERAPEUTIC DRUG USING ANTIBODY-DISPLAYING HOLLOW PROTEIN
NANOPARTICLES AND HOLLOW PROTEIN NANOPARTICLES

<130> 12480-000067/US

<140> 10509249

<141> 2004-09-28

<150> 10/509,249

<151> 2004-09-28

<160> 245

<170> PatentIn version 3.4

<210> 1

<211> 27

<212> DNA

<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 1

gctggtggtg gtggtggtgg tgggtggt

27

<210> 2

<211> 39

<212> DNA

<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 2

ctgagcctga gggctgcggc cgcctcccat gccttgctg

39

<210> 3

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 3
ggggacctcg gatccgcgag cttaccagtt ctcaca 36

<210> 4
<211> 36
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 4
gaggtcgacc agctttaacg aacgcagaat ttcga 36

<210> 5
<211> 33
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 5
ggccgctgga gccacccgca gttcgaaaaa ggc 33

<210> 6
<211> 33
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 6
ggccgccttt ttcgaactgc gggtaggctcc agc 33

<210> 7
<211> 29
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 7
ggggtaccat gagatctttg ttgatcttg 29

<210> 8
<211> 28
<212> DNA
<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 8

ggccgcggtt aaatgtatac ccaaagac

28

<210> 9

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 9

gggggcggcc gcgcgcaaca cgatgaagcc gtagac

36

<210> 10

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 10

ggttgagata aaagagcttt tggcgcggcc gccttt

36

<210> 11

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 11

cccgcggccg cccgaggaga cggtagactga ggtccc

36

<210> 12

<211> 36

<212> DNA

<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 12

gggggcggcc gcgatgtgca gttcaggag tcggga

36

<210> 13

<211> 30

<212> DNA
 <213> artificial sequence

 <220>
 <223> Synthesized Oligonucleotide

 <400> 13
 ggggcggccg ccttttattt ccaactttgt 30

 <210> 14
 <211> 30
 <212> DNA
 <213> artificial sequence

 <220>
 <223> Synthesized Oligonucleotide

 <400> 14
 ggggcggccg ccttttattt ccaactttgt 30

 <210> 15
 <211> 31
 <212> DNA
 <213> artificial sequence

 <220>
 <223> Synthesized Oligonucleotide

 <400> 15
 ccagttggac ggcggccgcc ctgcaccgaa c 31

 <210> 16
 <211> 31
 <212> DNA
 <213> artificial sequence

 <220>
 <223> Synthesized Oligonucleotide

 <400> 16
 gttcgggtgca gggcgccgc cgtccaactg g 31

 <210> 17
 <211> 34
 <212> DNA
 <213> artificial sequence

 <220>
 <223> Synthesized Oligonucleotide

 <400> 17
 caatccagat tggggcggcc gcctgcacc gaac 34

<210> 18
<211> 34
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 18
gttcggtgca gggcggccgc cccaatctgg attg

34

<210> 19
<211> 31
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 19
ggtaggagcg ggcggccgcc ctgcaccgaa c

31

<210> 20
<211> 31
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 20
gttcggtgca gggcggccgc ccgctcctac c

31

<210> 21
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 21
cctcaggccg gcggccgcc tgcaccgaac

30

<210> 22
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 22
gttcggtgca gggcggccgc cctgaggatg 30

<210> 23
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 23
gttcggtgca gggcggccgc cctgaggatg 30

<210> 24
<211> 31
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 24
cagagtgagg ggcggccgcc ctgcaccgaa c 31

<210> 25
<211> 31
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 25
gttcggtgca gggcggccgc ccctcactct g 31

<210> 26
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> Synthesized Oligonucleotide

<400> 26
ggtaggagcg ggcggccgca gccctcaggc 30

<210> 27
<211> 30
<212> DNA
<213> artificial sequence

<220>

<223> Synthesized Oligonucleotide

<400> 27

gcctgagggc tgcggccgcc cgctcctacc

30

<210> 28

<211> 10

<212> PRT

<213> artificial sequence

<220>

<223> artificial synthesized peptide sequence

<400> 28

Ser Ala Trp Arg His Pro Gln Phe Gly Gly

1 5 10

<210> 29

<211> 116

<212> PRT

<213> artificial sequence

<220>

<223> artificial synthesized peptide sequence

<400> 29

Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile

1 5 10 15

Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln

20 25 30

Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala

35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Val Asp Asn Lys Phe Asn

50 55 60

Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu

65 70 75 80

Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro

85 90 95

Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala

100 105 110

Gln Ala Pro Lys

115

<210> 30

<211> 39

<212> DNA

<213> artificial synthesized peptide sequence

<220>

<223> test fused

<400> 30

gctgctgctg ctgctgctag aagaagaaga agaagaaga

39

<210> 31

<211> 39

<212> DNA

<213> Artificial Sequence Fused Peptide

<220>

<223> 21-153 + ZZ (serotype y) sequence

<400> 31

gctgctgctg ctgctgctag aagaagaaga agaagaaga

39

<210> 32

<211> 378

<212> PRT

<213> artificial sequence

<220>

<223> protein corresponding to 21-153 + ZZ (serotype y) sequence

<400> 32

Met Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp

1

5

10

15

His Gln Leu Asp Gly Gly Arg Ala Gln His Asp Glu Ala Val Asp Asn

20

25

30

Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu

35

40

45

Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys

50

55

60

Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu

65	70	75	80
Asn Asp Ala Gln Ala Pro Lys Val Asp Asn Lys Phe Asn Lys Glu Gln	85	90	95
Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu	100	105	110
Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser	115	120	125
Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro	130	135	140
Lys Ala Ala Ala Pro Ala Pro Asn Met Glu Asn Thr Thr Ser Gly Phe	145	150	155
Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg	165	170	175
Ile Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn	180	185	190
Phe Leu Gly Gly Ala Pro Thr Cys Pro Gly Gln Asn Ser Gln Ser Pro	195	200	205
Thr Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly Tyr	210	215	220
Arg Trp Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu	225	230	235
Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met Leu	245	250	255
Pro Val Cys Pro Leu Leu Pro Gly Thr Ser Thr Thr Ser Thr Gly Pro	260	265	270
Cys Lys Thr Cys Thr Ile Pro Ala Gln Gly Thr Ser Met Phe Pro Ser	275	280	285
Cys Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile	290	295	300

Pro Ser Ser Trp Ala Phe Ala Arg Phe Leu Trp Glu Trp Ala Ser Val
 305 310 315 320

Arg Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val
 325 330 335

Gly Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp Met Met Trp Tyr
 340 345 350

Trp Gly Pro Ser Leu Tyr Asn Ile Leu Ser Pro Phe Leu Pro Leu Leu
 355 360 365

Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile
 370 375

<210> 33
 <211> 1134
 <212> DNA
 <213> artificial sequence

<220>
 <223> 21-153 (Q129R) + ZZ (serotype y) sequence

<400> 33
 atggggacga atctttctgt tccaatcct ctgggattct ttcccgatca ccagttggac 60
 ggcgccgcg cgcaacacga tgaagccgta gacaacaaat tcaacaaaga acaacaaaac 120
 gcgttctatg agatcttaca ttacctaac ttaacgaag aacaacgaaa cgccttcac 180
 caaagttaa aagatgaccc aagccaaagc gctaaccctt tagcagaagc taaaagcta 240
 aatgatgctc aggcgcgaa agtagacaac aaattcaaca aagaacaaca aaacgcgttc 300
 tatgagatct tacatttacc taacttaaac gaagaacaac gaaacgcctt catccaaagt 360
 ttaaaagatg acccaagcca aagcgctaac cttttagcag aagctaaaaa gctaaatgat 420
 gctcaggcgc cgaaagcggc cgccctgca ccgaacatgg agaacacaac atcaggattc 480
 ctaggacccc tgctcgtgtt acaggcgggg tttttcttgt tgacaagaat cctcacaata 540
 ccacagagtc tagactcgtg gtggacttct ctcaattttc tagggggagc acccacgtgt 600
 cctggccaaa attcgcagtc cccaacctcc aatcactcac caacctcttg tctccaatt 660
 tgtcctggct atcgctggat gtgtctgcgg cgttttatca tattcctctt catcctgctg 720
 ctatgcctca ttttcttgtt ggtttctctg gactaccaag gtatgttgcc cgtttgtcct 780

ctacttccag gaacatcaac caccagcacg gggccatgca agacctgcac gattcctget 840
cgaggaacct ctatgtttcc ctcttggtgc tgtacaaaac cttcggacgg aaactgcact 900
tgtattccca tcccatcacc ctgggctttc gcaagattcc tatgggagtg ggcctcagtc 960
cgtttctcct ggctcagttt actagtacca tttgttcagt ggttcgtagg gctttccccc 1020
actgtttggc tttcagttat atggatgatg tggattggg ggccaagtct gtacaacacc 1080
ttgagtcctt tttacacctt attaccaatt ttctttgtc tttgggtata catt 1134

<210> 34

<211> 378

<212> PRT

<213> artificial sequence

<220>

<223> Protein corresponding to 21-153 (Q129R) + ZZ (serotype y)
sequence

<400> 34

Met Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp
1 5 10 15

His Gln Leu Asp Gly Gly Arg Ala Gln His Asp Glu Ala Val Asp Asn
20 25 30

Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile Leu His Leu
35 40 45

Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys
50 55 60

Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu
65 70 75 80

Asn Asp Ala Gln Ala Pro Lys Val Asp Asn Lys Phe Asn Lys Glu Gln
85 90 95

Gln Asn Ala Phe Tyr Glu Ile Leu His Leu Pro Asn Leu Asn Glu Glu
100 105 110

Gln Arg Asn Ala Phe Ile Gln Ser Leu Lys Asp Asp Pro Ser Gln Ser
115 120 125

Ala Asn Leu Leu Ala Glu Ala Lys Lys Leu Asn Asp Ala Gln Ala Pro

130

135

140

Lys Ala Ala Ala Pro Ala Pro Asn Met Glu Asn Thr Thr Ser Gly Phe
145 150 155 160

Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg
165 170 175

Ile Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn
180 185 190

Phe Leu Gly Gly Ala Pro Thr Cys Pro Gly Gln Asn Ser Gln Ser Pro
195 200 205

Thr Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly Tyr
210 215 220

Arg Trp Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu
225 230 235 240

Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met Leu
245 250 255

Pro Val Cys Pro Leu Leu Pro Gly Thr Ser Thr Thr Ser Thr Gly Pro
260 265 270

Cys Lys Thr Cys Thr Ile Pro Ala Arg Gly Thr Ser Met Phe Pro Ser
275 280 285

Cys Cys Cys Thr Lys Pro Ser Asp Gly Asn Cys Thr Cys Ile Pro Ile
290 295 300

Pro Ser Ser Trp Ala Phe Ala Arg Phe Leu Trp Glu Trp Ala Ser Val
305 310 315 320

Arg Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val
325 330 335

Gly Leu Ser Pro Thr Val Trp Leu Ser Val Ile Trp Met Met Trp Tyr
340 345 350

Trp Gly Pro Ser Leu Tyr Asn Ile Leu Ser Pro Phe Leu Pro Leu Leu
355 360 365

Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile
 370 375

<210> 35
 <211> 1134
 <212> DNA
 <213> artificial sequence

<220>
 <223> 21-153 (G145R) + ZZ (serotype y) sequence

<400> 35
 atggggacga atctttctgt tcccaatcct ctgggattct ttcccgatca ccagttggac 60
 ggcgccgcg cgcaacacga tgaagccgta gacaacaaat tcaacaaaga acaacaaaac 120
 gcgttctatg agatcttaca ttacctaac ttaaacgaag aacaacgaaa cgccttcac 180
 caaagtttaa aagatgaccc aagccaaagc gctaaccttt tagcagaagc taaaagcta 240
 aatgatgctc aggcgccgaa agtagacaac aaattcaaca aagaacaaca aaacgcgttc 300
 tatgagatct tacatttacc taacttaaac gaagaacaac gaaacgcctt catccaaagt 360
 ttaaaagatg acccaagcca aagcgctaac cttttagcag aagctaaaaa gctaaatgat 420
 gctcaggcgc cgaaagcggc cgccctgca ccgaacatgg agaacacaac atcaggattc 480
 ctaggacccc tgctcgtgtt acaggcgggg tttttcttgt tgacaagaat cctcacaata 540
 ccacagagtc tagactcgtg gtggacttct ctcaatttct tagggggagc acccacgtgt 600
 cctggccaaa attcgcagtc cccaacctcc aatcactcac caacctcttg tctccaatt 660
 tgtcctggct atcgctggat gtgtctgcgg cgttttatca tattcctctt catcctgctg 720
 ctatgcctca tcttcttgtt ggttcttctg gactaccaag gtatgttgcc cgtttgtcct 780
 ctacttcag gaacatcaac caccagcacg ggcccatgca agacctgcac gattcctgct 840
 caaggaacct ctatgtttcc ctcttggtgc tgtacaaaac cttcggacag aaactgcact 900
 tgtattccca tcccatcatc ctgggcttcc gcaagattcc tatgggagtg ggcctcagtc 960
 cgtttctcct ggctcagttt actagtgcga tttgttcagt ggttcgtagg gctttccccc 1020
 actgtttggc tttcagttat atggatgatg tggatttggg ggccaagtct gtacaacatc 1080
 ttgagtcctt tttacctct attaccaatt tctttttgtc tttgggtata catt 1134

<210> 36
 <211> 378
 <212> PRT

<213> artificial sequence

<220>

<223> Protein corresponding to 21-153 (G145R) + ZZ (serotype y)
sequence

<400> 36

Met Gly Thr Asn Leu Ser Val Pro Asn Pro Leu Gly Phe Phe Pro Asp
1 5 10 15

His Gln Leu Asp Gly Gly Arg Ala Gln His Asp Glu Ala Val Asp Asn
20

Notice to Comply	Application No. 10/509,249	Applicant(s) Kuroda	
	Examiner Bo Peng	Art Unit 1648	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to completely comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: (1) CFR is defective, see attachment; (2) sequence listing is not as same as originally filed; see Para 5, the office action dated June 1, 2009.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
- ☒ An **amendment specifically directing its entry into the application.**

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

